Abstract
The research of new platinum drugs active towards cisplatin refractory/resistant tumors has been mostly focussed on compounds with cis geometry because transplatin, the trans-isomer of cisplatin, is inactive. It is widely accepted that transplatin inactivity stems from two major factors: i) the kinetic instability promoting its deactivation and ii) the formation of DNA adducts characterized by a regioselectivity and a stereochemistry different from those of cisplatin. However, several exceptions to the general rule that the presence of two leaving groups in cis positions is necessary for antitumor activity of platinum complexes, have been reported. Substitution of transplatin ammine ligands by aromatic Ndonor heterocycles, branched aliphatic amines, or imino ligands has lead to compounds with relevant in vitro tumor cell growth inhibitory potency, often active towards cisplatin refractory/resistant tumor cells, and in some cases endowed with significant activity also in vivo. From a mechanistic point of view, substitution of bulky ligands for ammines can retard substitution of the two chloride ligands, thus reducing the kinetic instability of the trans-platinum compounds. On the other hand, the formation of DNA adducts qualitatively and quantitatively different from those of cisplatin strongly supports the hypothesis that antitumor-active trans-platinum complexes can have a different spectrum of activity. It is hoped that the increasing knowledge of the biochemical and cellular processes underlying the antitumor-activity of transplatinum complexes will foster their clinical development.
Keywords: Platinum antitumor drugs, breast cancer, trans configuration, DNA interaction, cell cycle perturbation, gene expression profiling
Anti-Cancer Agents in Medicinal Chemistry
Title: Trans-Platinum Complexes in Cancer Therapy
Volume: 7 Issue: 1
Author(s): Mauro Coluccia and Giovanni Natile
Affiliation:
Keywords: Platinum antitumor drugs, breast cancer, trans configuration, DNA interaction, cell cycle perturbation, gene expression profiling
Abstract: The research of new platinum drugs active towards cisplatin refractory/resistant tumors has been mostly focussed on compounds with cis geometry because transplatin, the trans-isomer of cisplatin, is inactive. It is widely accepted that transplatin inactivity stems from two major factors: i) the kinetic instability promoting its deactivation and ii) the formation of DNA adducts characterized by a regioselectivity and a stereochemistry different from those of cisplatin. However, several exceptions to the general rule that the presence of two leaving groups in cis positions is necessary for antitumor activity of platinum complexes, have been reported. Substitution of transplatin ammine ligands by aromatic Ndonor heterocycles, branched aliphatic amines, or imino ligands has lead to compounds with relevant in vitro tumor cell growth inhibitory potency, often active towards cisplatin refractory/resistant tumor cells, and in some cases endowed with significant activity also in vivo. From a mechanistic point of view, substitution of bulky ligands for ammines can retard substitution of the two chloride ligands, thus reducing the kinetic instability of the trans-platinum compounds. On the other hand, the formation of DNA adducts qualitatively and quantitatively different from those of cisplatin strongly supports the hypothesis that antitumor-active trans-platinum complexes can have a different spectrum of activity. It is hoped that the increasing knowledge of the biochemical and cellular processes underlying the antitumor-activity of transplatinum complexes will foster their clinical development.
Export Options
About this article
Cite this article as:
Coluccia Mauro and Natile Giovanni, Trans-Platinum Complexes in Cancer Therapy, Anti-Cancer Agents in Medicinal Chemistry 2007; 7 (1) . https://dx.doi.org/10.2174/187152007779314080
DOI https://dx.doi.org/10.2174/187152007779314080 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Hypocalcemia Induced by Raloxifene
Current Drug Safety Mesenchymal Stem Cells in Veterinary Regenerative Therapy: Basic Physiology and Clinical Applications
Current Stem Cell Research & Therapy The Histone Deacetylase Inhibitor, MS-275 (Entinostat), Downregulates c-FLIP, Sensitizes Osteosarcoma Cells to FasL, and Induces the Regression of Osteosarcoma Lung Metastases
Current Cancer Drug Targets Exocrine Pancreas Involvement in Celiac Disease: A Review
Recent Patents on Inflammation & Allergy Drug Discovery Stroke in Women - Oral Contraception, Pregnancy, and Hormone Replacement Therapy
Current Vascular Pharmacology Liposomal Irinotecan in the Treatment of Refractory Pancreatic Cancer
Recent Patents on Anti-Cancer Drug Discovery Significance of P2X7 Receptor Variants to Human Health and Disease
Recent Patents on DNA & Gene Sequences Cardioprotective Effects of the Polyphenol Hydroxytyrosol from Olive Oil
Current Drug Targets Glucose Oncometabolism of Esophageal Cancer
Anti-Cancer Agents in Medicinal Chemistry Ethnopharmacological and Phytopharmaceutical Evaluation of Prosopis cineraria: An Overview and Future Prospects
Current Drug Metabolism Recent Advances in the Identification of Genetic and Biochemical Components of Breast Cancer Predisposition
Current Genomics Nanostructures as Promising Tools for Delivery of Antimicrobial Peptides
Mini-Reviews in Medicinal Chemistry The Common Mycobacterial Antigens and their Importance in the Treatment of Disease
Current Pharmaceutical Design Thirty Years of Polyamine-Related Approaches to Cancer Therapy. Retrospect and Prospect. Part 2. Structural Analogues and Derivatives
Current Drug Targets Role of Progesterone in Human Astrocytomas Growth
Current Topics in Medicinal Chemistry Editorial [Hot Topic: Overview of Antiangiogenic Therapies in Hematological Malignancies (Guest Editor: D. Ribatti)]
Current Cancer Drug Targets The Gut Mucosa as a Site for Induction of Regulatory T-Cells
Current Pharmaceutical Design Cancer Diagnosis and Disease Gene Identification <i>via</i> Statistical Machine Learning
Current Bioinformatics In Vitro Cytotoxic Activities of Platinum(II) Complex with 1-Methyl-2-(3'- hydroxypropyl)benzimidazole and 2-(3'-Hydroxypropyl)benzimidazolium Hexa- and Tetrachloroplatinate Salts
Letters in Drug Design & Discovery Targeted Radiosensitization in Prostate Cancer
Current Pharmaceutical Design